This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
*Some plans may not display due to a health plan-specific policy.
†Access is defined as having no formulary restrictions.
The information provided is not a guarantee of coverage of payment (partial or full) and is subject to change without notice.
Source: Managed Markets Insight and Technology. January 31, 2025. Pfizer Inc., New York, NY.
Order, track, and pay for PENBRAYA with Pfizer Prime
How to Transition to PENBRAYA
See how Pfizer can help your practice transition to PENBRAYA
Simplified Combination
See how PENBRAYA can help streamline meningococcal vaccination in your practice
Dosing and Recommendations
Learn about ACIP-recommended dosing for PENBRAYA
How to Transition to PENBRAYA
See how Pfizer can help your practice transition to PENBRAYA
Simplified Combination
See how PENBRAYA can help streamline meningococcal vaccination in your practice
Dosing and Recommendations
Learn about ACIP-recommended dosing for PENBRAYA
References: 1. Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345-350. 2. PENBRAYA® (Meningococcal Groups A, B, C, W, and Y Vaccine). Prescribing information. Pfizer Inc.; 2024. 3. Centers for Disease Control and Prevention. Meningococcal disease: meningococcal vaccine recommendations. Updated June 26, 2024. Accessed January 13, 2025. https://www.cdc.gov/meningococcal/vaccines/index.html
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2025 Pfizer Inc. All rights reserved.